Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Gilead Sciences Inc GILD

Healthcare Biotechnology
Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis, coronavirus disease 2019 (COVID-19) and cancer. It is focused on the discovery, development and commercialization of medicines in areas of unmet medical need. Its portfolio of marketed products... see more

Recent & Breaking News (NDAQ:GILD)

The Reason It Trades, What's Moving ELN, DELL, GILD and KEY

Marketwired May 23, 2013

European Medicines Agency Validates Gilead's Marketing Application for Sofosbuvir for the Treatment of Hepatitis C

Business Wire May 21, 2013

Start Making Profits Now With AMAT, BMY, GILD and RENN

Marketwired May 21, 2013

Profitable Trading Secrets Revealed in GILD, NWSA, RF and MTG

Marketwired May 18, 2013

Gilead Sciences to Present at the 2013 UBS Global Healthcare Conference on Monday, May 20

Business Wire May 17, 2013

Strategy Behind Our Success, We Get in Early: GILD, MCP, GM and DF

Marketwired May 16, 2013

Gilead Announces Response Data from Phase 2 Study of Idelalisib for Previously Untreated Chronic Lymphocytic Leukemia

Business Wire May 15, 2013

In the Know, Smart Investing in FCX, GILD, AIG and BMY

Marketwired May 15, 2013

Gilead Sciences to Present at the Bank of America Merrill Lynch 2013 Health Care Conference on Wednesday, May 15

Business Wire May 14, 2013

Special Situation Coming Soon, a Look Inside MS, GILD, FITB and WFR

Marketwired May 14, 2013

Secrets to Making Money in WCRX, T, GILD and IBM

Marketwired May 11, 2013

The Straight Truth, Investing in OXY, LULU, GILD and V

Marketwired May 10, 2013

Strategy Behind Our Success, We Get in Early: GILD, QCOM and DIS

Marketwired May 7, 2013

Key to Success, How to Profit: PM, WMT, GILD and SLB

Marketwired May 3, 2013

Gilead Sciences Announces First Quarter 2013 Financial Results

Business Wire May 2, 2013

Special Offer for Shareholders of GILD, SLB, CVS and DIS

Marketwired May 2, 2013

Gilead Receives Complete Response Letters from U.S. Food and Drug Administration for Elvitegravir and Cobicistat

Business Wire April 29, 2013

Key to Success, How to Profit: GILD, BMY, EBAY and FFIV

Marketwired April 26, 2013

Gilead Sciences to Release First Quarter 2013 Financial Results on Thursday, May 2, 2013

Business Wire April 25, 2013

StockCall Study on Gilead Sciences, NPS Pharma, InterMune, Seattle Genetics, and Halozyme Therapeutics

ACCESS Newswire April 24, 2013